Biocorp Archives - Medical Design Sourcing

Novo Nordisk acquires all shares of drug delivery device maker Biocorp

The Mallya smart insulin pen device pairs with the Novo Nordisk FlexTouch pen. [Image from Biocorp]Novo Nordisk today officially acquired 100% of the shares of Biocorp, the France-based drug delivery device maker’s CEO announced.

Biocorp designs, develops and manufactures drug delivery systems and medical devices. Its offerings include Mallya, a Bluetooth-enabled smart add-on device for pen injectors.

The Mallya smart sensor attaches directly to insulin pen injectors to make them connected devices. It automatically collects and records key treatment information, then transmits the information to a dedicated digital application. That data includes selected insulin units, date and time of injection. The FDA cleared Mallya in December 2022.

Get the full story at our sister site, Drug Delivery Business News.

8 drug delivery innovations you should know

Innovations in drug delivery never stop and, over the past 12 months or so, a wide variety have come under the spotlight.

Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing just how many ways we can deliver therapeutics.

About a year ago, we clued in readers to a list of six drug delivery innovations they should know. Here, we provide a couple of updates on those and try to introduce a few more developments that you should know:

The latest in automated insulin delivery tech

Automated insulin delivery represents one of the most high-profile markets in drug delivery, with the technology providing potentially life-saving therapy for people with diabetes.

The Mobi automated insulin pump with the accompanying mobile app. [Image courtesy of Tandem Diabetes Care]Last year’s roundup included the already FDA-cleared Omn…

Novo Nordisk looks to acquire a majority stake in BioCorp for $164.5M

The Mallya smart insulin pen device pairs with the Novo Nordisk FlexTouch pen. [Image from Biocorp]Novo Nordisk announced today that it entered into exclusive negotiations for a controlling stake in drug delivery device maker Biocorp.

France-based Biocorp specializes in the design, development and manufacturing of delivery systems and medical devices. Its offerings include Mallya, a Bluetooth-enabled smart add-on device for pen injectors.

Mallya, a smart sensor, attaches directly to insulin pen injectors to make them connected devices. It automatically collects and records key treatment information and transmits it to a dedicated digital application. That data includes selected insulin units, date and time of injection. The FDA cleared Mallya in December 2022.

Novo Nordisk and Biocorp have collaborated on Mallya’s development and commercialization since 2021. It pairs with the FlexTouch pen for people with diabetes. The two companies expanded their pa…

FDA clears Mallya smart insulin pen device from Biocorp

The Mallya smart insulin pen device. [Image from Biocorp]Biocorp announced today that it received FDA 510(k) clearance to market its Mallya smart medical device that connects insulin pens.

Mallya, a smart sensor, attaches directly to insulin pen injectors to make them connected devices. It automatically collects nad records key treatment information and transmits it to a dedicated digital application. That data includes selected insulin units, date and time of injection.

Get the full story at our sister site, Drug Delivery Business News.

Diabeloop announces integration of insulin automatization software for use with insulin pens

Diabeloop announced today that it leveraged its diabetes management software to integrate insulin pens into its hybrid closed-loop system.

Paris-based Diabeloop’s DBL-4pen, a unique app, offers new opportunities for the personalized management of people with type 1 and type 2 diabetes.

Get the full story at our sister site, Drug Delivery Business News.

BioCorp, Roche launch Mallya smart insulin pen in France

BioCorp and Roche Diabetes Care France announced the launch of the Mallya smart insulin pen device in France.

Developed by BioCorp, Mallya is an intelligent sensor for insulin injection pens that has CE mark approval in Europe. The platform is compatible with any disposable insulin pen. It enables reliable monitoring for doses selected for injection and it offers patients with diabetes better compliance with their treatment, according to the companies.

Get the full story at our sister site, Drug Delivery Business News.

MedTech 100 roundup: Slight rise for the industry

While medtech’s performance still isn’t mirroring the beginning of 2021, the industry is showing signs of life with a small improvement last week.

The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the index hitting its lowest recent point on March 8 (102.16), marking a fall at a level not seen since October.

Even after a slight rise earlier this month, the index struggled again two weeks ago with another small dip. However, after coming in at 104.05 on March 19, the index got a slight boost over the past week, finishing at 104.87 on March 26, representing a 0.8% rise.

Despite the up-and-down nature of the past couple of months, the index represents a much better situation for the industry compared to this time a year ago when the COVID-19 pandemic was in full swing. The index is up 13.6% from its pre-p…

BioCorp, Diabeloop partner on diabetes management tech development

BioCorp and Diabeloop announced today that they are entering a cooperation agreement to develop new personalized diabetes treatments.

Diabeloop develops automated insulin delivery (AID) systems, including a self-learning algorithm hosted in a handset and connected to a continuous glucose monitoring (CGM) system and an insulin pump. The platform analyzes glucose data, calculates the right dose of insulin for administration and automatically administers it.

BioCorp develops Mallya, an intelligent sensor for insulin injection pens that has CE mark approval in Europe. The platform is compatible with any disposable insulin pen and enables reliable monitoring for doses selected for injection and it offers patients with diabetes better compliance with their treatment.

Get the full story at our sister site, Drug Delivery Business News.